The United States platelet rich plasma market size reached US$ 226.7 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 403.9 Million by 2028, exhibiting a growth rate (CAGR) of 10% during 2023-2028.
Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).
The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country. Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market report, along with forecasts at the country and regional level from 2023-2028. Our report has categorized the market based on product type, origin, application and end user.
Breakup by Product Type:
Pure Platelet-Rich Plasma (P-PRP)
Leukocyte- and Platelet-Rich Plasma (LPRP)
Leukocyte- and Platelet-Rich Fibrin (L-PRF)
Pure Platelet-Rich Fibrin (P-PRF)
Breakup by Origin:
Breakup by Application:
Cosmetic Surgery and Dermatology
Breakup by End User:
Hospitals and Clinics
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.
Base Year of the Analysis
Product Type, Origin, Application, End User, Region
Northeast, Midwest, South, West
Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The United States platelet rich plasma market was valued at US$ 226.7 Million in 2022.
We expect the United States platelet rich plasma market to exhibit a CAGR of 10% during 2023-2028.
The rising consumer awareness towards numerous benefits associated with platelet rich plasma treatment, such as preventing inflammation, encouraging new cartilage formulation, inducing natural lubrication fluid production, etc., is primarily driving the United States platelet rich plasma market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cosmetic, orthopedics, and neuro surgical procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the United States market for platelet rich plasma.
Based on the product type, the United States platelet rich plasma market has been divided into Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich Plasma (LPRP), Leukocyte- and Platelet-Rich Fibrin (L-PRF), and Pure Platelet-Rich Fibrin (P-PRF). Among these, Pure Platelet-Rich Plasma (P-PRP) currently exhibits a clear dominance in the market.
Based on the origin, the United States platelet rich plasma market can be categorized into autologous PRP, homologous PRP, and allogeneic PRP. Currently, autologous PRP accounts for the majority of the total market share.
Based on the application, the United States platelet rich plasma market has been segregated into orthopedics, cosmetic surgery and dermatology, neurosurgery, general surgery, cardiothoracic surgery, urology, ophthalmology, and others. Among these, orthopedics currently exhibit a clear dominance in the market.
Based on the end user, the United States platelet rich plasma market can be bifurcated into hospitals and clinics, research institutes, and others. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into Northeast, Midwest, South, and West, where West currently dominates the United States platelet rich plasma market.
Some of the major players in the United States platelet rich plasma market include Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc., and Zimmer Biomet Holdings Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.